Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature.
This is the first description in which the diagnosis of vanishing bile duct syndrome (VBDS) preceded the diagnosis of Hodgkin disease (HD) by several months, and for which patients received modifications to modern MOPP-ABV chemotherapy with successful clinical remission. VBDS is an uncommon form of liver disease manifested by severe cholestasis and progressive liver failure. We report 2 cases of stage IIIB pediatric HD and VBDS. Because VBDS is progressive and the only curative treatment is liver transplant, it is imperative to recognize that children with VBDS may also have concurrent HD.
Pass
Amy Kun
AK
Texas Children's Cancer Center, USA. akpass@txccc.org
McLin
Valerie A
VA
Rushton
Jennifer R
JR
Kearney
Debra L
DL
Hastings
Caroline A
CA
Margolin
Judith F
JF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002779:Cholestasis / Q000175:diagnosis* / Q000188:drug therapy; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013577:Syndrome; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D011241:Prednisone